CoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan
February 23, 2016CoLucid Pharmaceuticals, Inc., announced today the completion of a preclinical /in vivo /study examining the effect of lasmiditan on coronary and carotid artery diameters.
More »
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
February 11, 2016Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases
More »
Five Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
January 21, 2016Based on the preliminary data, Five Prime plans to continue evaluating FPA144 as a monotherapy in refractory gastric cancer, as a combination therapy in the front-line gastric cancer setting and as a potential treatment for other types of cancer.
More »